Skip to main content

Month: March 2023

Kvika banki hf.: Annual General Meeting 30 March 2023 – Candidacy to the Board and amended proposals of the BoD

The deadline for candidacy to the Board expired on 25 March 2022. The following candidates have submitted their application for the Board of Directors at the AGM, to be held on 30 March, at 4:00 pm at Grand Hotel, Háteigur, Sigtún 28, 150 Reykjavík, also accessible online through Lumi AGM: In candidacy for the Board of Directors:Sigurður Hannesson Guðmundur Þórðarson Guðjón Reynisson Helga Kristín Auðunsdóttir Ingunn Svala LeifsdóttirIn candidacy as alternate members:Helga Jóhanna Oddsdóttir Sigurgeir GuðlaugssonIt is the assessment of the Board that all candidacies are valid in accordance with Act No. 2/1995 respecting Public Limited Companies. According to the company’s articles of association the Board of Directors shall consist of five members and two alternate members.  As no further candidates have applied for the Board...

Continue reading

07/2023 Green Hydrogen Systems – Financial calendar 2023 (updated)

Company announcement 07/2023 Green Hydrogen Systems updates financial calendar for 2023 Kolding, Denmark, 27 March 2023 – Green Hydrogen Systems A/S hereby updates its financial calendar for 2023: Q1 2023 Trading Statement:        17 April 2023 (updated) Annual General Meeting:        18 April 2023 Q2 2023 Interim Report:        22 August 2023 Q3 2023 Trading Statement:        1 November 2023 For more info please contact: Investors: Jens Holm Binger, Head of Investor Relations, +45 6065 6525, jhb@greenhydrogen.dk Media: Jesper Buhl, Head of Public Affairs and Media Relations, +45 5351 5295, jbu@greenhydrogen.dk Green Hydrogen Systems in brief Green Hydrogen Systems is a clean technology company and a leading provider of standardised and modular electrolysers for the production of green hydrogen solely based on renewable energy. With its...

Continue reading

Surgical Suture Market is Expected to Cross USD 6.75 Billion by 2030 at a CAGR of 5.7% from 2022 to 2030; Prevalence of Chronic Diseases coupled with the Rising Number of Surgical Procedures Performed Worldwide to Push Market Growth

SkyQuest’s report on the surgical suture market is an extensive study that provides valuable insights. The report has been prepared using a robust methodology. It offers a comprehensive market analysis, including a SWOT analysis, technology assessment, economic evaluation, product benchmarking, recent developments, and accurate forecasting. A report is essential for businesses looking to enter or expand in the market. It helps understand the current market scenario, identify the key players operating in the market, and analyze their market share, strategies, and critical developments. The report’s accurate forecasting also assists businesses in making informed decisions and developing effective strategies for growth. Westford USA, March 27, 2023 (GLOBE NEWSWIRE) — According to a study by SkyQuest in 2022, a heart attack...

Continue reading

Professional Diversity Network Acquires Additional Equity Interest in RemoteMore USA, Inc.

CHICAGO, March 27, 2023 (GLOBE NEWSWIRE) — Professional Diversity Network, Inc. (NASDAQ:IPDN) (“PDN” or the “Company”), a developer and operator of online and in-person networks that provide access to networking, training, educational and employment opportunities for diverse individuals, announced the acquisition of additional 20% of equity interest in RemoteMore USA, Inc. (“RemoteMore”) on March 23, 2023, an online platform specializing in remote-hiring of software developers, increasing PDN’s ownership position in RemoteMore to approximately 66% after the transaction. Recognizing the unstoppable trend of remote working and the surged demand of a curated workforce pool, PDN purchased approximately 46% of equity interest in RemoteMore back in September 2021. Since that acquisition, RemoteMore has continuously grown its revenue...

Continue reading

Imperial Petroleum Announces Management Estimate of Net Asset Value Per Share- $1.39

ATHENS, Greece, March 27, 2023 (GLOBE NEWSWIRE) — Imperial Petroleum Inc. (Nasdaq: IMPP) (the “Company”), a ship-owning company providing petroleum products, crude oil, and drybulk seaborne transportation services, announced today that at March 27, 2023 the Company’s management, estimates Imperial Petroleum Inc’s Net Asset Value (“NAV”) to be $338.6 million, which is approximately 717% above its current market capitalization. The NAV which includes total outstanding cash of $142.2 million is increasing daily on account of the record net cashflow contributed by our tankers. This translates into a NAV of $1.39 per common share currently outstanding and $1.17 per common share on a fully diluted basis (assuming exercise of all outstanding warrants for cash). NET ASSET VALUE (“NAV”) The estimated NAV represents a snapshot in time as...

Continue reading

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Data to be presented at AACR demonstrate significant SP-3164 anticancer activity in both non-Hodgkin Lymphoma and Multiple Myeloma cell lines and animal models Targeted protein degrader SP-3164 on track for IND submission in first half of 2023 with clinical trial to begin in second half of 2023 HOUSTON, March 27, 2023 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three and 12 months ended December 31, 2022 and provided a business update. Financial HighlightsCash and cash equivalents were $12.1 million as of December 31, 2022, compared with $29.2 million as of December 31, 2021. Subsequent to the close...

Continue reading

Timbercreek Financial ranks on The Globe and Mail’s fourth-annual Women Lead Here benchmark of executive gender diversity for a third year

TORONTO, March 27, 2023 (GLOBE NEWSWIRE) — Timbercreek Financial (“Timbercreek”) is pleased to announce it has been included on The Globe and Mail’s 2023 Report on Business magazine’s Women Lead Here list for a third straight year. This annual editorial benchmark identifies top-notch Canadian businesses with the highest executive gender diversity. The ranking companies have made tangible and organizational progress related to executive gender parity. This benchmark was established in 2020 by Report on Business magazine and applies a proprietary research methodology to determine Canadian corporations with the highest degree of gender diversity among executive ranks. “It is a privilege to be among the most gender-diverse corporations in Canada for a third consecutive year,” said Blair Tamblyn, CEO of Timbercreek. “We are extremely...

Continue reading

LPL Financial Welcomes SC Financial Group

CHARLOTTE, N.C., March 27, 2023 (GLOBE NEWSWIRE) — LPL Financial LLC announced today that SC Financial Group has joined LPL Financial’s broker-dealer, RIA and custodial platforms. The team reported having served approximately $220 million in advisory, brokerage and retirement plan assets*, and joins LPL from Cadaret Grant & Co, now part of the Atria Group. Financial advisors Shane Cloninger and Susan Carter, who has since retired, founded the Bellevue, Wash.,- based practice in 2008 with a mission to deeply understand and foster each client’s true needs and financial goals. The multigenerational practice has evolved over the years to include fellow advisors Robert Davis, Rumesh Senanayake and Alex Carter, Susan’s son. The team focuses heavily on retirement income strategies, investor education and portfolio management, often...

Continue reading

Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC (“Concentra”) will acquire Jounce for $1.85 in cash per share plus a non-tradeable contingent value right (the “CVR”). The $1.85 per share upfront consideration represents a premium of approximately 75% to Jounce’s closing share price immediately prior to the March 14, 2023 public disclosure...

Continue reading

LianBio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Phase 3 trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) ongoing, with data expected mid-year 2023 Phase 3 registrational trial of TP-03 in Chinese patients with Demodex blepharitis ongoing, with data expected in the fourth quarter of 2023 Entered into commercial agreement with Pfizer, with Pfizer opting into LianBio rights to RSV therapeutic candidate sisunatovir in LianBio territories Cash, cash equivalents and marketable securities of $302.4 million with runway through the end of 2024 SHANGHAI, China and PRINCETON, N.J., March 27, 2023 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today reported financial results for the fourth quarter and year ended December...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.